Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
暂无分享,去创建一个
Pierre Blanchard | Gilles Calais | Jean Bourhis | J. Pignon | G. Calais | J. Bourhis | A. Paccagnella | R. Hitt | P. Blanchard | J. Vermorken | M. Posner | A. Bourredjem | Marshall R Posner | B. Lacas | Adriano Paccagnella | Jan B Vermorken | Jean-Pierre Pignon | Abderrahmane Bourredjem | Ricardo Hitt | Benjamin Lacas | Juan J Cruz Hernandez | J. C. Cruz Hernández
[1] G. Calais,et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] F. Khuri,et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. , 2013, The Lancet. Oncology.
[3] R. Weber,et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] E. Vokes,et al. DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). , 2012 .
[5] J. Pignon,et al. Mixed treatment comparison meta-analysis of altered fractionated radiotherapy and chemotherapy in head and neck cancer. , 2011, Journal of clinical epidemiology.
[6] R. Tishler,et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. , 2011, The Lancet. Oncology.
[7] A. Paccagnella,et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] R. Hitt,et al. Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] G. Calais,et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. , 2009, Journal of the National Cancer Institute.
[10] J. Pignon,et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[11] M. Karamouzis,et al. Head and neck cancer , 2008, The Lancet.
[12] T. Gorlia,et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. , 2007, The New England journal of medicine.
[13] A. Markoe,et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. , 2007, The New England journal of medicine.
[14] J. Carles,et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Thompson,et al. Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.
[16] J. Pignon,et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta analysis of chemotherapy on head and neck cancer , 2001 .
[17] J. Bourhis,et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data , 2000, The Lancet.
[18] M Schemper,et al. A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.
[19] L. Stewart,et al. Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group. , 1995, Statistics in medicine.
[20] M. Parmar,et al. Meta-analysis of the literature or of individual patient data: is there a difference? , 1993, The Lancet.
[21] Anthony Howell,et al. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .
[22] A. D. Schryver,et al. Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women: 1 , 1992 .
[23] R. Peto,et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.